Trials / Completed
CompletedNCT01568580
Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A
Open-label, Non-comparative, Multicenter, Phase III for Evaluation of Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Previously Treated Patients With Hemophilia A
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to study the evaluation of efficacy and safety of GreenGene (Recombinant Factor VIII).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GreenGene | Dose : 10 \~ 50IU/kg Administration method : intravenous infusion or bolus |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2006-09-01
- Completion
- 2006-09-01
- First posted
- 2012-04-02
- Last updated
- 2012-04-02
Source: ClinicalTrials.gov record NCT01568580. Inclusion in this directory is not an endorsement.